title: Histamine lipolysis I: changes in the free fatty acid levels of dog plasma after intravenous infusion of histamine.
abstract: The effects of histamine (Hi) and related compounds on free fatty acid (FFA) levels and % changes in FFA composition of dog plasma were studied after intravenous infusion. Hi at doses of 2-10 micrograms/kg while affecting no changes in the cardiovascular system elicited a dose-related increase in FFA levels in plasma, as did epinephrine. Though all of the FFA concentrations in plasma were increased by Hi infusion, % change of each FFA in the composition did not correspond to that of plasma concentration; % increases in palmitoleic acid, linolenic acid and linoleic acid were remarkable, while stearic acid (18:0) was lowest. The increase in arachidonic acid was not marked, but a dose-related increase was observed after Hi infusion. The H2-agonist 4-methylHi produced an increase in FFA levels, whereas the H1-agonist 2-methylHi was not effective. 4-MethylHi increased all of the plasma FFA levels and the relative changes were similar to those caused by Hi. The effect induced by Hi was blocked by the H2-antagonists cimetidine and ranitidine. Pretreatment with aminophylline potentiated the Hi effect, indicating that Hi lipolysis may be intimately related to cyclic AMP.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Okayama University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Akiyama
authors.forename: T
authors.initials: T
authors.lastname: Mukai
authors.forename: C
authors.initials: C
authors.lastname: Kamei
authors.forename: K
authors.initials: K
authors.lastname: Tasaka
mesh_terms: D000628:Aminophylline / Q000494:pharmacology; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004155:Diphenhydramine / Q000494:pharmacology; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006632:Histamine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006633:Histamine Antagonists / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007262:Infusions, Intravenous; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D008761:Methylhistamines / Q000494:pharmacology; D010424:Pentobarbital; D011738:Pyrilamine / Q000494:pharmacology; D013217:Starvation
chemical_list: D005230:Fatty Acids, Nonesterified; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D008761:Methylhistamines; D000628:Aminophylline; C025566:4-methylhistamine; D006632:Histamine; D004155:Diphenhydramine; C026259:2-methylhistamine; D011738:Pyrilamine; D010424:Pentobarbital; D004837:Epinephrine